Quarterly report pursuant to Section 13 or 15(d)

Financial Instruments (Tables)

v3.8.0.1
Financial Instruments (Tables)
9 Months Ended
Sep. 30, 2017
Fair Value Disclosures [Abstract]  
Available-for-sale Securities [Table Text Block]
The composition of financial instruments as of December 31, 2016 is as follows:
 
December 31, 2016
Amortized
Cost
 
Gross Unrealized
 
Fair
Value
Gains
 
Losses
 
 
(in thousands)
Assets
 
 
 
 
 
 
 
Money market funds
$
39,181

 
$

 
$

 
$
39,181

Government debt securities
28,025

 

 
(32
)
 
27,993

Corporate debt securities
25,923

 

 
(7
)
 
25,916

 
93,129

 

 
(39
)
 
93,090

Less amounts included in cash and cash equivalents
(39,181
)
 

 

 
(39,181
)
 
$
53,948

 
$

 
$
(39
)
 
$
53,909

 
Fair Value at December 31, 2016
 
(in thousands)
Liabilities
 
Contingent consideration
$
375

Total
$
375


Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]
he following table presents a summary of the Company’s financial instruments that were measured at fair value on a recurring basis as of December 31, 2016:
 
 
 
Fair Value Measurements at December 31, 2016
 
Balance at December 31, 2016
 
Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)
 
Significant
Other
Observable
Inputs
(Level 2)
 
Significant
Unobservable
Inputs
(Level 3)
 
(in thousands)
Assets
 
 
 
 
 
 
 
Money market funds
$
39,181

 
$
39,181

 
$

 
$

Government debt securities
27,993

 

 
27,993

 

Corporate debt securities
25,916

 

 
25,916

 

 
$
93,090

 
$
39,181

 
$
53,909

 
$

Liabilities
 
 
 
 
 
 
 
Contingent consideration
$
375

 
$

 
$

 
$
375

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]
he following summarizes the activity in Level 3 financial instruments:
 
Nine Months Ended September 30,
 
2017
 
2016
 
(in thousands)
Contingent Consideration (1)
 
 
 
Beginning balance
$
375

 
$
395

Physpeed earn-out payment
(375
)
 
(240
)
Loss recognized in net income(2)

 
209

Ending balance
$

 
$
364

Net loss for the period included in net income attributable to contingent consideration held at the end of the period
$

 
$
(209
)
_